Clofarabine

Drugs in R and D

Volumn 5, Issue 4, 2004, Pages 213-217

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CLOFARABINE; CYTARABINE; DNA DIRECTED DNA POLYMERASE BETA; ORPHAN DRUG; OXIDOREDUCTASE; PURINE; PURINE NUCLEOSIDE DERIVATIVE; RIBOSE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BLAST CELL CRISIS; CANADA; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COOPERATION; DIARRHEA; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS INHIBITION; DRUG ERUPTION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; EUROPEAN UNION; FEVER; GEOGRAPHIC DISTRIBUTION; HALOGENATION; HUMAN; JAPAN; LEUKEMIA; LICENCE; LIVER TOXICITY; LYMPHOMA; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; SKIN MANIFESTATION; SOLID TUMOR; SOUTHEAST ASIA; STOMATITIS; TREATMENT OUTCOME; UNITED STATES;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CLINICAL TRIALS; HUMANS; LEUKEMIA;

EID: 4143101222     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200405040-00005     Document Type: Article

References (17)

1. Bioenvision Inc. Bioenvision Extends Exclusive Option to Market Clofarabine in Japan and Southeast Asia. Media Release: 18 May 2004. Available from URL: http://www.bioenvision.com
2. Bioenvision Inc, Bioenvision Receives Milestone Payment in Anticipation of Completed NDA Filing of Clofarabine. Media Release: 2 Feb 2004. Available from URL: http://www.bioenvision.com
3. Genzyme Corporation, ILEX Oncology Inc. Genzyme Corporation to Acquire ILEX Oncology, Inc. Media Release: 26 Feb 2004. Available, from URL: http://www.genzyme.com
4. Bioenvision inc. Bioenvision Obtains Exclusive Option to Market Clofarabine in Japan and South East Asia. Media Release: 10 Sep 2003. Available from URL: http://www.bioenvision.com
5. Bioenvision Inc. Bioenvision's Clofarabine Obtains Fast Track Designation for Pediatric Leukemia. Media Release: 9 Sep 2003. Available from URL: http://www.bioenvision.com
6. Bioenvision Inc. Bioenvision Reports Interim Data from European Phase II Trial of Clofarabine First Line in Adult AML; 64% Response Rate Seen in Older Adult Patients with Acute Myeloid Leukemia. Media Release: 21 Apr 2004. Available from URL: http://www.bioenvision.com
7. Bioenvision Inc. Bioenvision's Trial of Clofarabine in Adult Acute Leukemia Exceeds Expectations; Study Closed Early To Expedite Enrollment In Pivotal Studies. Media Release: 19 May 2004. Available from URL: http://www.bioenvision.com
8. Bioenvision Inc. Interim Results for Bioenvision's Clofarabine Reported at 39th Annual Meeting of American Society of Clinical Oncology. Media Release: 2 Jun 2003. Available from URL: http://www.bioenvision.com
9. Bioenvision Inc. Bioenvision Commences European Pivotal Phase II Study in Pediatric Acute Lymphoblastic Leukemia. Media Release: 16 Sep 2003. Available from URL: http://www.bioenvision.com
10. Bioenvision Ltd. First Patient Enters Pivotal European Phase II Pediatric Leukemia Study for Bioenvision's Clofarabine. Media Release: 4 Dec 2003. Available from URL: http://www.bioenvision.com
11. Gandhi V, Kantarjian HM, Faderl S, et al. Cellular pharmacokinetics and pharmacodynamics of clofarabine (2-chloro-2′-fluoro-arabinosyladenine) in acute leukemia blasts during a phase I clinical trial. 93rd Annual Meeting of the American Association for Cancer Research - Supplement: 77-78 (plus poster), 6 Apr 2002
12. Jeha SC, McDonald LR, Chan K, et al. Clofarabine (Clofarex) is an active agent in pediatric leukemias. 38th Annual Meeting of the American Society of Clinical Oncology 21: 397 (plus poster), 18 May 2002
13. Faderl S, Gandhi V, Cortes J, et al. Clofarabine is active as a single agent and in combination with ara-C in patients with relapsed/refractory acute leukemias and high-risk myelodsyplastic syndrome. 39th Annual Meeting of the American Society of Clinical Oncology: 586, 31 May 2003
14. ILEX Oncology Inc. CLOFAREX shows early promise in both pediatric and adult relapsed/refractory acute leukemias. Media Release: [3 pages], 10 Dec 2001. Available from URL: http://www.ilexonc.com
15. Jeha A, Steinherz P, Razzouk B, et al. A phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute-myelogenous or lymphoblastic leukemia. 39th Annual Meeting of the American Society of Clinical Oncology: 809 (plus poster) abstr. 3251, 31 May 2003
16. Bioenvision Inc. Bioenvision's Clofarabine Data Presented at Leukemia 2002 Conference. Media Release: 15 Oct 2002. Available from URL: http://www.bioenvision.com
17. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103: 784-789, No. 3, 1 Feb 2004